Spoken Alpha
Passage BIO, Inc.
Passage Bio develops gene therapies for neurodegenerative diseases. The company's lead program, PBFT02, is a one-time gene therapy designed to restore progranulin levels in the brain to treat frontotemporal dementia caused by progranulin deficiency, with expansion into other neurodegenerative conditions including ALS and Alzheimer's disease.
Passage BIO, Inc is a Healthcare company operating in Biotechnology with a $16.2M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 8, 2026).
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PASG.
$ curl https://api.spokenalpha.com/v1/companies/PASGFAQ
Spoken Alpha indexes PASG's earnings call transcripts at https://spokenalpha.com/companies/PASG. Each call links to attributed speakers and parsed analyst Q&A. Passage BIO, Inc.'s own investor relations page is at https://www.passagebio.com/investors-and-news/overview/default.aspx.
Passage BIO, Inc. (PASG) held its most recent earnings call on 2023-03-06, covering fiscal Q4 2022.
Passage BIO, Inc. (PASG) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-08 | — | $-2.16 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-09 | $-2.44 | $-2.20 | -10.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $-2.36 | $-3.06 | +22.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-4.09 | $-2.80 | -46.1% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-2.44 | $-2.97 | +17.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.96 | $-4.15 | +28.7% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-5.00 | $-4.47 | -11.9% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-0.20 | $-0.20 | 0.0% | $3.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-4.71 | $-4.67 | -0.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-5.20 | $-6.20 | +16.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-6.00 | $-6.90 | +13.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-03 | $-0.30 | $-0.40 | +25.0% | $5.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-7.93 | $-8.80 | +9.9% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-8.80 | $-9.55 | +7.8% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-12.60 | $-10.15 | -24.1% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-05 | $-0.49 | $-0.52 | +5.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-9.80 | $-15.44 | +36.5% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-14.60 | $-15.93 | +8.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-15.80 | $-18.38 | +14.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.95 | $-0.89 | -6.7% | $0 | — | — | EODHD |
Source: EODHD. PASG reported actuals as published; sparse fields render as —.